Loading the security page…
A security analysis is not yet prepared for this market.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
AbCellera Biologics Inc. (ABCL) is a company in the Health care sector; its shares trade on Nasdaq.
The price of AbCellera Biologics Inc. (ABCL) on November 9, 2026 is 12.59 $, +5.98 % on the day. Over 52 weeks the stock traded between 2.75 $ and 15.02 $; the price now sits 80 % of the way up that range. Over the past year the price changed by +100.36 %. Market capitalization is 3.65 billion $, rank 49 among 380 stocks of the same industry with a known capitalization.
AbCellera Biologics Inc. trades on Nasdaq under the ticker ABCL. The company belongs to the Health care sector. The trading history on this page starts on 11 December 2020.
Over the past 52 weeks ABCL has traded between 2.75 $ and 15.02 $. As of 9 November 2026 the price stood 68.26% of the way from the 52-week low to the high.
Over one year ABCL shares rose 100.36%; over six months they rose 142.27%. Volatility over 90 days is 94.51%. Dividends are not included: this is price change only, as of 9 November 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 55.1, above the sector median of 3.6. Price to book is 4.1, above the sector median of 2.3. Calculated from reports for the period ending 30 June 2026.
AbCellera Biologics Inc. reported revenue of 66M $ and a net loss of 165M $ over the last four quarters. Net margin is −248.84%. Revenue changed by +101.27% year over year. Earnings per share are −$0.54. Market capitalisation is 3.6B $.
ABCL has a return on equity of −18.38%, above the sector median of −40.58%. Return on assets is −12.59%, above the sector median of −30.08%. Operating margin is −340.27%, below the sector median of −20.96%.